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The human immunodeficiency virus type 1 (HIV-1) vpu gene product is a class I integral membrane phosphoprotein that
is capable of oligomerization. Two distinct biological activities have been attributed to Vpu: induction of CD4 degradation in
the endoplasmic reticulum and enhancement of viral particle release from the plasma membrane of infected cells. These two
biological activities were shown to involve two separable structural domains: the N-terminal transmembrane (TM) domain
and the C-terminal cytoplasmic domain. The TM domain mediates enhancement of viral particle release, whereas phos-
phorylation of the cytoplasmic domain is essential for Vpu-induced CD4 degradation. In this study, we performed a mutational
analysis of the TM domain of Vpu to delineate amino acids that are important in the process of viral particle release or in
Vpu-induced CD4 degradation. Substitution of conserved amino acids from the N-terminal, middle, or C-terminal parts of the
native VpuTM domain generated proteins that integrated normally into canine pancreatic microsomal membranes, exhibited
subcellular localization similar to those of wild-type Vpu, but partially lost their ability to enhance viral particle release,
strongly suggesting that the VpuTM domain contains determinants responsible for Vpu-mediated enhancement of viral
particle release. Interestingly, the C-terminal TM mutant VpuIVW, in contrast to the other mutants, also lost its ability to bind
and consequently degrade the CD4 molecule, indicating that the alteration of the C-terminal part of the TM did interfere with
this function of Vpu. Taken together, our study supports the notion that both structural elements of Vpu (TM and cytoplasmic)
contribute to the biological activities of Vpu. © 1998 Academic Press
INTRODUCTION
Vpu is an 81-amino-acid integral membrane phospho-
protein that is capable of homo-oligomerization (Mal-
darelli et al., 1993; Strebel et al., 1989). This protein is
encoded exclusively by human immunodeficiency virus
type 1 (HIV-1) and is not found in any other primate
lentiviruses such as HIV-2 or in most Simian immunode-
ficiency viruses (Cohen et al., 1988; Matsuda et al., 1988;
Strebel et al., 1988). Biochemical studies have shown
that Vpu has the topology of a class I integral membrane
protein with an N-terminal hydrophobic domain of 27
amino acids, a charged C-terminal hydrophilic domain,
and no discernible extracellular domain (Maldarelli et al.,
1993; Wray et al., 1995). The N-terminal hydrophobic
domain functions in anchoring the protein to the mem-
brane, whereas so far the catalytic activity has been
attributed to the cytoplasmic domain (Chen et al., 1993;
Schubert et al., 1994). This domain contains two phos-
phoacceptor sites, serine residues 52 and 56, located
within the highly conserved C-terminal stretch of 12
amino acids (residues 47–58), which are phosphorylated
by the ubiquitous casein kinase II protein (Friborg et al.,
1995; Schubert et al., 1992, 1994).
Two main biological activities have been attributed to
Vpu: specific induction of CD4 degradation in the endo-
plasmic reticulum (ER) and enhancement of viral particle
release from the plasma membrane (Subbramanian and
Cohen, 1994). There are several lines of evidence that
suggest that the two biological functions of Vpu are
mechanistically distinct and occur within two different
compartments. Vpu-induced CD4 degradation relies on
the efficient phosphorylation of both phosphoacceptor
sites, whereas it had only a partial effect on Vpu-facili-
tated release (Friborg et al., 1995; Schubert and Strebel,
1994). Moreover, Vpu-mediated CD4 degradation is
highly specific in terms of cellular location and sequence
requirements: it occurs in the ER and requires the pres-
ence of sequences in both the CD4 transmembrane (TM)
and cytoplasmic domains (Buonocore et al., 1994; Chen
et al., 1993; Lenburg and Landau, 1993; Raja et al., 1994;
Vincent et al., 1993; Yao et al., 1995). Conversely, the role
of Vpu in augmenting viral particle release occurs at the
plasma membrane and does not appear to be specific to
HIV-1 because divergent retroviruses can more effi-
ciently release their viral particles in the presence of a
functional Vpu (Go¨tllinger et al., 1993). Furthermore, the
Vpu protein has been shown to be localized predomi-
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nantly in the perinuclear region of HIV-1-infected cells,
and it is not found in viral particles (Klimkait et al., 1990).
Some progress has been made in understanding the
underlying mechanisms of CD4 degradation. Vpu-medi-
ated degradation of CD4 was shown to be sensitive to
proteasome-specific inhibitors and to be dependent on
the presence of an intact ubiquitination machinery (Fujita
et al., 1997; Schubert et al., 1998). Furthermore, recent
experiments using the two-hybrid system have identified
a novel human protein, bTrCP, that interacts with Vpu/
CD4 and possibly functions as part of a ubiquitin–protein
ligase that catalyzes the ubiquitination of CD4 (Margottin
et al., 1998). In contrast, the molecular basis in the
regulation of virus release by Vpu has yet to be clearly
defined. The observation that Vpu facilitates release of
divergent retrovirus puts forth the possibility that Vpu
somehow indirectly alters the intracellular milieu near
the plasma membrane. This activity can be linked to a
Vpu ion channel (Ewart et al., 1996; Schubert et al.,
1996b) even though the data that we have obtained in
Xenopus oocytes does not support an ion channel, at
least at the level of the plasma membrane (Coady et al.,
1998).
Through mutational analysis, several studies have
identified sequences, structural determinants, or both in
the TM domain and cytoplasmic tail of CD4 and in the
cytoplasmic tail of Vpu that are involved in CD4 degra-
dation (Buonocore et al., 1994; Chen et al., 1993; Lenburg
and Landau, 1993; Raja et al., 1994; Tiganos et al., 1997;
Yao et al., 1995). However, the role of the TM domain of
Vpu with respect to the dual functions of Vpu has yet to
be clearly elucidated. Experiments using Vpu deletion
mutants and mutants containing a randomized TM do-
main have demonstrated that the TM domain of Vpu
represents an active domain important for the regulation
of virus release but not CD4 degradation (Schubert et al.,
1996a). In addition, recent experiments have demon-
strated the importance of the structural integrity of the
TM domain of Vpu in the release of virus-like particles
using chimeric Vpu proteins (Paul et al., 1998). This study,
however, did not elaborate further on previous findings
by this same group that suggested the involvement of the
TM domain of Vpu in the degradation of Vpu-sensitive
glycoproteins (Raja and Jabbar, 1996).
To gain further insight into the mechanism of Vpu-
mediated CD4 degradation and release and to particu-
larly assess the importance of the membrane-spanning
domain in Vpu-associated activities, we performed a
focused mutational analysis of the hydrophobic TM do-
main of native Vpu. The results show that substitution of
conserved amino acids from the N-terminal, middle, or
C-terminal parts of the native VpuTM domain generated
proteins that integrated normally into canine pancreatic
microsomal membranes (CMMs), exhibited subcellular
localization similar to those of wild-type Vpu, but partially
lost their ability to enhance viral particle release. Inter-
estingly, the C-terminal TM mutant VpuIVW also lost its
ability to bind and consequently degrade the CD4 mole-
cule, indicating that the alteration of the C-terminal part
of the TM did interfere with this function of Vpu. Taken
together, our study supports the notion that both the
structural elements of Vpu (TM and cytoplasmic) contrib-
ute to the biological activities of Vpu.
RESULTS
Construction of HIV-1 VpuTM mutants
To analyze the role and importance of the membrane-
spanning domain of Vpu for the biological activities of the
protein, a panel of substitution mutations were intro-
duced into the 27-amino-acid hydrophobic TM region of
Vpu by PCR-directed mutagenesis. To minimize potential
interference to membrane integration, the hydrophobic
nature of the TM domain was left unchanged by intro-
ducing semiconservative mutations. All of the mutants
constructed, however, affected the conserved sequence
and amino acid organization of different regions of the
TM domain of Vpu, respectively. Mutants VpuKSL and
VpuF8I9 were generated to introduce substitutions
within the N-terminal portion of the TM domain (Fig. 1).
VpuKSL contains a 3-amino-acid substitution in which
Ile6, Ile8, and Val9 were replaced by Lys, Ser, and Leu,
respectively, and contains a positively charged amino
acid in an area that is void of charge. Mutant VpuF8I9
harbors a 2-amino -acid substitution, whereby Ile8 and
Val9 were replaced by the aromatic amino acid residue
Phe and the neutral Ile residue, respectively. Mutant
VpuF13V14 contains a 2-amino-acid substitution
whereby Val13 and Ala14 were changed to Phe and Val
and was primarily designed to affect the integrity of the
middle region of the TM domain by introducing an aro-
matic amino acid residue. Finally, mutant VpuIVW is
located at the C-terminal portion of the TM domain and
carries a 3-amino-acid substitution whereby Val21, Trp22,
and Ile24 were replaced by Ile, Val, and Trp, respectively.
This mutant was primarily designed to displace the
highly invariant Trp22 residue and consequently affect
the integrity of the C-terminal part of the TM domain.
Membrane association of VpuTM mutants
Before studying the functions of these Vpu mutants,
we first evaluated the ability of each mutant to integrate
into cellular membranes. Run-off transcripts from the Vpu
expression plasmids, including pSP64-Vpu or pSP64 Vpu
mutants, were translated in an in vitro rabbit reticulocyte
lysate system in the presence of CMMs. As a negative
control, transcripts from a HIV-1 Vpr expression plasmid
was also translated under the same conditions. Previous
studies have shown that in vitro translation in the pres-
ence of CMMs is useful in elucidating the topology of a
number of viral proteins, including Vpu, in biological
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membranes (Haffar et al., 1988; Korman et al., 1992;
Maldarelli et al., 1993; Strebel et al., 1989). After the
translation reaction, translated products were treated
with sodium carbonate at alkaline pH, which has been
shown to release cytosolic proteins from microsomal
membrane preparations (Fujiki et al., 1982), as described
in Materials and Methods. After centrifugation, mem-
brane and supernatant fractions were immunoprecipi-
tated with a Vpu antiserum and subsequently analyzed
on a 12.5%–SDS polyacrylamide gel followed by autora-
diography. As shown in Fig. 2, a 16-kDa translation prod-
uct corresponding to wild-type Vpu was immunoprecipi-
tated from the membrane pellet fraction (lane 1). In con-
trast, no Vpu was detectable in the supernatant fraction
(lane 2). Similarly, all the mutations introduced in the
N-terminal region of Vpu (VpuKSL, VpuF8I9, VpuF13V14,
and VpuIVW) produced proteins that were immunopre-
cipitated from the membrane pellet fraction (Fig. 2, com-
pare lanes 3–10). In contrast, the Vpr protein, which
presumably was non-membrane bound, was found pre-
dominantly within the supernatant fraction and served as
the negative control (Fig. 2, lanes 11 and 12). From this
result, it is clear that the mutations introduced in the
hydrophobic TM region did not affect the membrane-
integration ability of Vpu.
Effect of mutations in the hydrophobic N-terminal
region of Vpu on Vpu-mediated enhancement of
release
To analyze the impact of the alterations introduced into
the TM domain of Vpu on its ability to enhance virus
particle release, we studied the effect of Vpu in trans on
the release of virus particles from HeLa-CD8 cells. These
cells were cotransfected with HXBH10 env2/vpu2 and
SVCMVVPU2, SVCMVVPU1, or SVCMV mutant Vpu ex-
pression plasmids. The release of viral particles into the
supernatant was evaluated by measuring the virus-asso-
ciated reverse transcriptase (RT) activity at 48 h post-
transfection.
The data presented in Table 1 show that the wild-type
Vpu protein increases by 2.4-fold the amount of virus
exported from cells compared with that in the absence of
FIG. 1. Mutagenesis of the VpuTM domain. Schematic representation of the structural domain of the Vpu protein and amino acid (aa) sequence of
its TM. Mutations were introduced into the predicted 27-aa N-terminal hydrophobic region of Vpu by PCR-based mutagenesis (see Materials and
Methods). The altered aa are indicated in bold.
FIG. 2. In vitro translation of Vpu mutants in presence of CMMs.
Run-off RNA transcripts from pSP64-vpu1 (lanes 1 and 2), pSP64-vpu
KSL (lanes 3 and 4), pSP64-vpu F8I9 (lanes 5 and 6), pSP64-vpu F13V14
(lanes 7 and 8), pSP64-vpu IVW (lanes 9 and 10), and pSP64-vpr (lanes
11 and 12) were translated in rabbit reticulocyte lysate in the presence
of CMMs at 30°C. At the end of the translation reaction, samples were
treated with 0.1 M sodium bicarbonate (Na2CO3), pH 11, for 30 min on
ice. After this treatment, samples were sedimented by centrifugation,
and microsomal membrane pellets (P) and supernatant fractions (S)
were collected, immunoprecipitated with an anti-Vpu serum, separated
on a 12.5% SDS–polyacrylamide gel, and visualized by autoradiography.
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a functional Vpu protein. On the other hand, in the pres-
ence of the VpuTM mutants, the enhanced release of
viruses from the cotransfected cells was shown to be
impaired (RT values were comparable to Vpu2) (Table 1).
To confirm these observations, we also evaluated the
release of viral particles by the more sensitive radioim-
munoprecipitation assay using HIV-1-positive human se-
rum. The amount of viral protein released in the super-
natant of transfected cells was determined by comparing
the ratio of virion-associated capsid protein (p24gag) to
total capsid protein in the presence of wild-type Vpu or
different VpuTM mutants provided in trans. (Fig. 3A, com-
pare lanes 1–12). Cells that express wild-type Vpu re-
lease 5-fold more capsid protein than their Vpu2 coun-
terpart (Fig. 3B). In contrast, cells that express each of
the VpuTM mutants show an impairment of ;2- to 3-fold
in capsid protein release (Fig. 3B). From these results,
we could conclude that mutations introduced in the TM
domain of Vpu impair the ability of the protein to opti-
mally enhance viral particle release.
Subcellular localization of VpuTM domain mutants
To address whether the altered biological activity dis-
played by the various VpuTM mutants was not due to a
potential change in the subcellular localization relative to
wild-type Vpu, COS-7 cells were transfected with SVCMV-
Vpu2, SVCMVVpu1, or SVCMV-mutant Vpu. Intracellular
localization was evaluated by an indirect immunofluores-
cence technique using the rabbit anti-Vpu peptide serum as
described in Materials and Methods. As shown in Figure
4B and as described previously (Klimkait et al., 1990), spe-
cific fluorescence labeling of wild-type Vpu can be readily
detected in a perinuclear region of the cytoplasm as an
intense staining. Furthermore, some specific Vpu staining
can be detected dispersed throughout the cytoplasm ex-
tending to the plasma membrane (Fig. 4B). A similar pattern
of perinuclear staining can be seen with mutants VpuKSL,
VpuF8I9, VpuF13V14, and VpuIVW (Figs. 4C–4F), whereas
no specific fluorescence labeling was detected with the
negative Vpu2 control plasmid (Fig. 4A). Therefore, we can
conclude that the altered biological activity of the Vpu mu-
tants was not due, at least at a gross level, to a change in
subcellular localization.
Effect of hydrophobic TM domain mutations on Vpu-
induced CD4 degradation
To determine the effect of the different VpuTM mutants
on CD4 degradation, the turnover of wild-type CD4 was
assessed in the presence of wild-type or mutated Vpu by
pulse-chase experiments as shown in Fig. 5A. COS-7
cells were cotransfected with both SVCMV-CD4 and
SVCMV-Vpu1 or Vpu mutant expressors at a CD4-to-Vpu
molar ratio of 1:3. At 48 h posttransfection, COS-7 cells
were pulse-labeled, chased up to 5 h, and lysed in RIPA
lysis buffer. Cell lysates were first immunoprecipitated
with anti-CD4 monoclonal antibodies and subsequently
with a polyclonal anti-Vpu serum. The rate of CD4 decay
was densitometrically determined by scanning the auto-
radiograms. The levels of CD4 present at different times
were calculated relative to the amounts detected at the
beginning of the chase (which was defined as 100%). The
t1/2 of CD4 was .5 h in the absence of Vpu, whereas it
was reduced to ;1 h in the presence of wild-type Vpu
(Fig. 5B). VpuTM mutant F8I9 was able to degrade CD4
as fast as wild-type Vpu, whereas mutant KSL and
F13V14 were slightly impaired (CD4 t1/2 5 2h and 3.5 h,
respectively). Conversely, VpuTM mutant IVW was un-
able to degrade CD4 (CD4 t1/2 5 .5 h).
To verify whether the impairment observed with some
mutants for CD4 degradation was not due to the instability
of these mutated Vpu proteins, cell lysates were subse-
quently immunoprecipitated with the anti-Vpu serum. Re-
sults indicate that both VpuF8I9 and VpuF13V14 exhibit
similar stability profiles with a t1/2 of ;4 h (Fig. 5C). Mutants
VpuKSL and VpuIVW, on the other hand, showed half-lives
similar to that of wild-type Vpu, with a t1/2 of .5 h (Fig. 5C).
Hence, the slight impairment in CD4 degradation demon-
strated by mutant VpuKSL cannot be correlated to the
instability of this mutated protein. On the other hand, mutant
VpuF13V14, which is less stable, still degrades CD4, albeit
at a reduced level. In contrast, mutant VpuIVW, which is as
stable as VpuWT, does not degrade CD4. Interestingly,
immunoprecipitation experiments consistently demonstrate
greater protein levels with mutant VpuKSL at time 0 or
reduced protein levels with mutant VpuF8I9 compared with
VpuWT (Fig. 5A, compare lanes 9 and 13 with lane 5). This
indicates that the context within which these mutations
were introduced may have rendered these proteins more or
less efficiently translated in our assay system. We cannot,
however, exclude the possibility that these proteins exhibit
differential affinities compared with VpuWT for antibody
recognition. Therefore, mutations affecting the N-terminal
or middle portion of the hydrophobic TM region did not
abolish Vpu-mediated CD4 degradation; however, muta-
tions in the C-terminal portion completely abrogated this
activity.
TABLE 1
Effect of Vpu on Export of Viral Particles in Trans
Vpu expressor
RT activity (103 3 cpm)
HXBH10-Vpu2/env2
SVCMV Vpu2 15.0 6 1.9
SVCMV Vpu1 35.3 6 3.8
SVCMV VpuKSL 15.1 6 1.5
SVCMV VpuF8I9 16.4 6 2.1
SVCMV VpuF13V14 11.3 6 2.5
SVCMV VpuIVW 14.5 6 1.8
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Implication of the VpuTM domain in the interaction
between Vpu and CD4 molecules
In an attempt to explore the possible mechanisms
involved in the impairment of CD4 degradation, we
tested the CD4 binding ability of the VpuTM mutants by
pulse-chase analysis as described in Material and Meth-
ods. Because Vpu-induced CD4 degradation is sensitive
to proteasome inhibitors (Fujita et al., 1997; Schubert et
al., 1998), these experiments were conducted in the pres-
ence of the proteasome inhibitor MG-132. This allowed
us to maintain similar levels of CD4 available for Vpu
interaction and eliminate variability due to degradation of
FIG. 3. The effect of VpuTM domain on enhancement of virus particle release. (A) Eleven micrograms of SVCMVvpu2, SVCMVvpu1, or SVCMVvpu
mutant was cotransfected with 10 mg of HXBH10-vpu2/env2 in HeLa-CD8 cells. At 48 h posttransfection, cells were radiolabeled for 8 h. Both cells
and the corresponding clarified supernatants then were lysed, immunoprecipitated with an HIV-1-positive human serum, and analyzed on a
12.5%–SDS polyacrylamide gel. The mock-transfected HeLa-CD8 cells are shown in lane M. The positions of HIV-1 p24gag and p55gag are indicated.
(B) P24gag protein detected in the cell lysate and clarified supernatant was quantified with a PhosphorImager. The amount of p24gag protein exported
in the supernatant was calculated as the percentage of total p24gag for each sample. Values are representative of three independent experiments.
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the CD4 molecule. Quantification analysis of bound
VpuWT to CD4 was defined as 100%, and this value
represents the levels of bound Vpu relative to the total
amount of immunoprecipitated Vpu and to the level of
CD4 detected in each sample. Although VpuWT and
VpuF8I9 were shown to be efficiently coimmunoprecipi-
tated with CD4 (Fig. 6A, lanes 2–3 and lanes 6–7), only
traces of VpuIVW were found to interact with CD4 (Fig.
6A, lanes 10 and 11). This inability of mutant VpuIVW to
interact with CD4 is consistent with the inability of a
previously described a-helix I mutant (VpuYRK) to inter-
act with CD4, which serves as a negative control (Fig. 6A,
lanes 12 and 13) (Tiganos et al., 1997). Furthermore,
mutants VpuKSL and VpuF13V14 retain their inherent
ability to be coimmunoprecipitated with CD4 although
less efficiently than VpuWT (Fig. 6A, compare lanes 4
and 5 and 8 and 9 with lanes 2 and 3). Densitometric
scanning of autoradiograms of Fig. 6A shows that ;,5%
of VpuIVW was bound to CD4 compared with VpuWT
(100%) and VpuYRK (13%) (Fig. 6C). Conversely, mutations
introduced in the N-terminal and central parts of the TM
domain retained the ability of the protein to interact with
CD4. Mutant VpuF8I9, which degrades CD4, retained
67% of its ability to interact with CD4, whereas mutants
VpuKSL and VpuF13V14, which are partially impaired in
CD4 degradation, retained ;40% and ;36% of their
CD4-binding ability, respectively (Fig. 6C). Taken to-
gether, these results demonstrate that there is a corre-
lation between the degree of Vpu binding to CD4 and the
extent of degradation.
DISCUSSION
It has previously been demonstrated that Vpu has two
independent biological activities: enhancement of viral
particle release from the surface of infected cells and the
specific degradation of the HIV-1 receptor molecule CD4
in the ER (Subbramanian and Cohen, 1994). Moreover, it
has been suggested that these two biological activities
of Vpu operate via two distinct molecular mechanisms
and involve two different structural domains of the Vpu
protein. The N terminus of Vpu encoding the TM domain
has been suggested to represent an active domain im-
portant for regulation of virus release but not for CD4
degradation, whereas phosphorylation of the cytoplas-
mic domain is important for Vpu-induced CD4 degrada-
tion. Using the infectious molecular clone of HIV-1 ex-
pressing the native Vpu protein, we performed a muta-
tional analysis of the VpuTM domain in an attempt to
better understand the structural requirements of this
domain with respect to each biological function.
The relative contribution of the VpuTM domain with
FIG. 4. Subcellular localization of VpuTM mutants. COS-7 cells transfected with Vpu-expressing plasmids were fixed with a solution of
ethanol–acetone (75%:25%) and sequentially stained with rabbit anti-Vpu and FITC-conjugated goat anti-rabbit sera. A largely perinuclear distribution
of Vpu was observed in cells expressing wild-type Vpu (B), VpuKSL (C), VpuF8I9 (D), VpuF13V14 (E), and VpuIVW (F). No staining was observed with
the negative control Vpu2 (A).
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respect to both of the biological activities of Vpu has yet
to be clearly defined. Studies have shown that with
respect to virus release, mutants that express only the
first 32 amino acids of Vpu in essence have the potential
of expressing the entire N-terminal TM domain but only
partially support virus release compared with wild-type
Vpu (Schubert et al., 1996a). Furthermore, Schubert and
Strebel (1994) and Friborg et al. (1995) demonstrated that
Vpu-mediated enhancement of virus release was par-
tially dependent on Vpu phosphorylation of both serine
residues (52 and 56) in the cytoplasmic domain of Vpu;
mutants that had both sites mutated exhibited interme-
diate levels of virus release. In contrast, experiments
with a scrambled VpuTM domain and, more recently,
studies using chimeric Vpu proteins have attributed to
the VpuTM domain exclusive activity in regulating Vpu-
enhanced virus release (Schubert et al., 1996a; Paul et
al., 1998). To begin to address some of the mechanistic
discrepancies of Vpu action in virus release, we concen-
trated on mutating conserved amino acid sequences
within the native VpuTM domain. Our findings suggest
that mutations in the N-terminal, middle, or C-terminal
parts of the VpuTM domain have generated proteins that
are partially defective in enhancement of virus release
compared with VpuWT. This phenotype suggests the
VpuTM domain contains determinants that modulate vi-
rus release. However, the fact that these VpuTM mutants
exhibited a partial activity with the more sensitive radio-
FIG. 5. Effect of mutations in the N-terminal hydrophobic region of Vpu on the rate of CD4 degradation. (A) COS-7 cells were cotransfected with
5 mg of SVCMVCD4 plasmid and 12.5 mg of SVCMVVpu1, SVCMVVpu2, or a plasmid encoding a VpuTM mutant as indicated. At 48 h posttransfection,
cells were pulse-labeled for 20 min and chased in complete DMEM supplemented with 10 mM BFA. At the indicated time periods, radiolabeled cells
were lysed and immunoprecipitated, first with the anti-CD4 monoclonal antibody and subsequently with the anti-Vpu serum, as indicated. The
immunoprecipitated CD4 and Vpu proteins were then analyzed on a 12.5%–SDS polyacrylamide gel. CD4 and Vpu bands from the autoradiogram are
shown in the top panel. The rate of CD4 decay (B) and the steady-state level of the Vpu mutant proteins (C) were quantified by densitometric scanning.
The levels of CD4 and Vpu present at the different time intervals were calculated relative to the amounts detected at the beginning of the chase (which
was defined as 100%). The data are representative of results obtained in three different experiments.
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FIG. 6. CD4-binding abilities of VpuTM domain mutants. COS-7 cells were cotransfected with 8 mg of wild-type CD4 expression plasmid and 12.5
mg of Vpu1 (lanes 2 and 3), VpuKSL (lanes 4 and 5), VpuF8I9 (lanes 6 and 7), VpuF13V14 (lanes 8 and 9), VpuIVW (lanes 10 and 11), and VpuYRK (lanes
12 and 13) expression plasmid. At 48 h posttransfection, cells were pretreated with MG-132 and BFA and subsequently pulse-labeled for 20 min and
chased for 0 or 90 min in complete DMEM in the presence of MG-132 and BFA. After lysis with 0.5% digitonin lysis buffer, cell lysates were
immunoprecipitated first with the anti-CD4 monoclonal antibody (A) and subsequently with the anti-Vpu serum (B). Immunoprecipitates were
separated on a 12.5%–SDS polyacrylamide gel and visualized by autoradiography. The positions of CD4 and Vpu are indicated on the right.
Quantification of Vpu bound to CD4 is shown by the histogram at the bottom (C). These values represent the levels of bound Vpu mutants relative
to the total amount of immunoprecipitated Vpu and to the level of CD4 detected in each sample. The value obtained with the positive control Vpu1
was defined as 100%. The densitometric values obtained were reproducible with standard deviations of ,10%.
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immunoprecipitation assay above the constitutive level
as observed with Vpu2 suggests that the VpuTM domain
does not contain the sole determinants that regulate
virus release. Alternatively, it is possible that the muta-
tions that were introduced in this domain did not neu-
tralize the active sites responsible for Vpu-mediated en-
hancement of virus release. We tend to favor the first
suggestion because both structural domains of Vpu con-
tribute to optimal virus release. Our exhaustive muta-
tional analysis of the VpuTM domain has never produced
a mutant that completely abrogated Vpu-mediated en-
hancement of viral release.
Until now, there has been some discrepancy in the
literature regarding the relative contribution of the
VpuTM domain with respect to Vpu-induced CD4 degra-
dation. Studies by Schubert et al. (1996a) demonstrated
that Vpu mutants carrying randomized TM domains are
capable of degrading CD4 with wild-type efficiency. In
contrast, studies conducted by Raja and Jabbar (1996)
using chimeric Vpu proteins have strongly suggested
that the VpuTM domain does play a role in the degrada-
tion of Vpu-sensitive glycoprotein. Moreover, recent mu-
tational analysis performed on the VpuTM domain by this
same group did not address this issue (Paul et al., 1998).
To this extent, we provided evidence demonstrating that
mutations affecting conserved sequences in the N-ter-
minal or middle part of the VpuTM domain had little effect
on Vpu-induced CD4 degradation. Conversely, mutations
affecting the C-terminal part of VpuTM (VpuIVW) severely
abrogated CD4 proteolysis. Because we previously dem-
onstrated along with others that the interaction of Vpu
with CD4 is a prerequisite leading to Vpu-induced CD4
degradation (Bour et al., 1995; Tiganos et al., 1997), we
subjected our VpuTM mutants to an in vivo binding as-
say. Our results demonstrate that a VpuTM mutant
(VpuF8I9) that is capable of degrading CD4 with wild-
type efficiency retains its binding affinity for this viral
receptor. Furthermore, mutants that are partially attenu-
ated with respect to CD4 degradation (VpuKSL and
VpuF13V14) demonstrate decreased binding efficiencies
to CD4. In contrast, the binding affinity of mutant VpuIVW
was completely abolished, at least within the sensitivity
of our assay. These results further substantiate the cor-
relation that exists between CD4 degradation and Vpu
binding.
From a structural point of view, Vpu is a low-molecular-
weight (16-kDa) integral membrane phosphoprotein that
lacks a cleavable signal sequence (Strebel et al., 1989).
The majority of the proteins with an uncleaved signal
sequence use a signal–anchor (S–A) domain that serves
to both target the protein to the ER and act as a stop-
transfer to stably anchor the protein into membranes
(Haeuptle et al., 1989; High et al., 1991). Class I integral
membrane proteins with S–A domains are poorly char-
acterized. The most common feature of class I mem-
brane proteins of the S–A type is the absence or low
number of positively charged amino acid residues at the
N-terminal side of the hydrophobic segment (High et al.,
1991). The proximal portion of the N-terminal sequence
of Vpu illustrates such a feature (Fig. 1). Furthermore, it
has been shown that the presence of Trp residue at the
interface of the N- and C-terminal regions of class I
membrane proteins may fulfill the stop-transfer function
and stabilize the a-helix of the protein with respect to
lipid bilayers (Landolt-Marticorena et al., 1993). The am-
phiphatic character of Trp and Tyr side chains alterna-
tively may allow this protein segment a degree of vertical
mobility with respect to the lipid bilayer (Pawagi and
Deber, 1990). Interestingly, Trp at position 22 in the Vpu
amino acid sequence is conserved in all Vpu1 HIV-1
isolates. In this study, we demonstrated that mutant
VpuIVW, which has its Trp residue moved from position
22 to 24, has lost its ability to interact and subsequently
degrade CD4. Consequently, it is plausible that by having
its Trp residue repositioned, this mutant has potentially
lost an inherent degree of vertical mobility that has re-
sulted in a suboptimal conformational change. The re-
sulting perturbance caused in the structural integrity of
this part of the VpuTM domain may affect the immediate
downstream Vpu–CD4 binding interface that has been
previously described (Tiganos et al., 1997) and impede
the interaction with CD4. Alternatively, we cannot refute
the possibility that the C-terminal part of the VpuTM
domain contains determinants that may be involved in
the early recognition events precluding Vpu-induced
CD4 degradation. Indeed, the nonrandom distribution
observed for amino acids in the TM and boundary do-
mains of type I membrane proteins suggests that these
segments are involved in cellular processes beyond an-
choring the protein to the membrane (Landolt-Marti-
corena et al., 1993).
Although we have not defined the exact nature of the
molecular mechanism controlled by the VpuTM domain
in the processes of viral particle release and CD4 deg-
radation, we provide new evidence suggesting that the
VpuTM domain contributes to both biological activities of
Vpu. Although we concur with the literature that both
structural domains represent two distinct molecular do-
mains, we provide evidence that there is a relative con-
tribution by each domain vis-a`-vis both biological activi-
ties. More detailed structural analyses will be required to
determine the relationship among the structure, function,
and mechanism of action of the Vpu protein during HIV-1
infection.
MATERIALS AND METHODS
Site-directed mutagenesis and plasmid DNA
constructions
HXBH10-vpu1 (LTR-gag1, pol1, vif1, vpr2, tat1, rev1,
vpu1, env1, nef2-LTR) and HXBH10-vpu2 (LTR-gag1,
pol1, vif1, vpr2, tat1, rev1, vpu2, env1, nef2-LTR) are
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two isogenic infectious molecular clones of HIV-1 that
differ only in their ability to express Vpu (Yao et al., 1992).
Vpu mutagenesis was performed on HXBH10-vpu1 using
a two-step PCR-based mutagenesis as previously de-
scribed (Ho et al., 1989). The nucleotide sequences of
the mutagenic oligonucleotides were as follows:
HXBH10-VpuKSL, sense: 59-CCTATACAAAAAGCAAGCT-
TAGCATTAGTA-39; HXBH10-VpuF8I9, sense: 59-ACAAAT-
AGCATTCATCGCATTAGTAG-39; HXBH10-VpuF13V14,
sense: 59-AGCATTAGTCTTCGTGATAATAATAG-39;
HXBH10-VpuIVW, sense: 59-AGCAATAGTTATAGTCTCCT-
GGGTAATCATAG-39. A pair of oligonucleotide primers
located 23 bp upstream from the vpr initiation codon
(sense primer A: 59-AAGCCACCTTTGCCTAGT-39) and
148 bp downstream from the vpu termination codon (an-
tisense primer B: 59-GGCTACACAGGCATGTGT-39) were
used for DNA amplification of the mutated fragments.
The generated Vpu mutated fragments were then di-
gested at SalI and KpnI sites located at positions 5331
and 5893, respectively (11 5 site of transcription initia-
tion of the HXBH10 molecular clone) and cloned into the
in vitro expression plasmid pSP64 (Promega) to yield
pSP64-VpuKSL, pSP64-VpuF8I9, pSP64-VpuF13V14, and
pSP64-VpuIVW. The pSP64-Vpr expression plasmid has
been previously described (Cohen et al., 1990). The re-
sulting Vpu mutants were then amplified by PCR using a
second pair of primers and subsequently cloned into the
linearized (XbaI–KpnI) expression plasmid SVCMVVpu as
previously described (Tiganos et al., 1997). The HIV-1
Vpu-expressing plasmid SVCMVVpu1, the negative con-
trol plasmid SVCMVVpu2, and the SVCMVCD4 used in
this study have been previously described (Tiganos et
al., 1997). All mutant constructs were confirmed by the
dideoxynucleotide chain termination sequencing method
using a Sequenase kit (United States Biochemical Co.,
Cleveland, OH).
Antibodies and chemical compound
The rabbit anti-Vpu serum was raised by immunizing
rabbits with a synthetic peptide corresponding to amino
acids 73–81 of the BH10 Vpu protein (Cohen et al., 1988).
The anti-CD4 (OKT4) monoclonal antibodies were de-
rived from ascitic fluids of Balb/c mice that were injected
with an OKT4 hybridoma obtained from the American
Type Culture Collection (Rockville, MD). Brefeldin A (BFA)
was obtained from Sigma Chemical (St. Louis, MO) and
stored as a 10 mM stock solution in ethanol at 220°C.
Digitonin was purchased from Aldrich Chemical. MG-132
was purchased from Peptide International and was
stored as a 10 mM stock solution in DMSO at 220°C.
In vitro transcription and translation
RNAs were synthesized by in vitro transcription of
linearized SP64 plasmids DNA using SP6 RNA polymer-
ase in the presence of 5 mM 7mGpppG cap analog
(Pharmacia LKB Biotechnology) as described previously
(Cohen et al., 1988). Equimolar amounts of the transcrip-
tion mixtures containing the appropriate mRNAs were
then translated in the presence of CMMs (7 Eq/50-ml
reaction) in a rabbit reticulocyte lysate system (Promega)
as described previously (Cohen et al., 1988). Translation
was carried out at 30°C for 30 min in presence of 50 mCi
of L-[35S]methionine (NEN Translation Grade) and
stopped by chilling on ice.
Membrane incorporation of Vpu
In vitro translated reactions were treated using 0.1 M
sodium carbonate at pH 11 for 30 min on ice and were
sedimented by centrifugation of the translation mixtures
for 1 h in an airfuge (Beckman Instruments Inc., Palo Alto,
CA) at 20 psi of air pressure. Membrane pellets and
supernatant fractions were collected; solubilized in a
buffer containing 140 mM NaCl, 8 mM NaHPO4, 2 mM
NaH2PO4, 1% Nonidet-P40, 0.5% sodium deoxycholate,
and 0.05% SDS at a neutral pH; and immunoprecipitated
with a rabbit anti-Vpu peptide serum as described pre-
viously (Cohen et al., 1988). The labeled immunoprecipi-
tates were separated on a 12.5% SDS–polyacrylamide
gel and visualized by autoradiography.
Cells and DNA transfection
HeLa-CD8, a human epithelial-like cell line, and
COS-7, an African green monkey kidney cell line trans-
formed by an origin-defective mutant of Simian virus 40
(SV40), were maintained in DMEM (GIBCO Laboratories)
containing 10% FBS. COS-7 cells (1.1 3 106) were co-
transfected with a mixture of 5 mg of a CD4 expressor
(SVCMV-CD4) and 15 mg of SVCMVVpu (wild-type or
mutant) expression plasmid DNA (molar ratio 1:3) using
a calcium phosphate method (Yao et al., 1995). HeLa-
CD8 cells were seeded similarly but were otherwise
cotransfected with a mixture of 10 mg of proviral HxBH10
env2/vpu2 and 12.0 mg of SVCMVVpu wild-type or mu-
tant expression plasmid DNA (molar ratio 1:3) using the
calcium phosphate method.
Virus-specific RT activity in the supernatant fluid was
measured as described previously (Yao et al., 1992).
Metabolic labeling and radioimmunoprecipitation
CD4-degradation experiments were all performed 48 h
posttransfection. Transfected cells were pretreated with
10 mM BFA for 30 min and metabolically labeled with 200
mCi of [35S]methionine and [35S]cysteine (11 mCi/ml
Trans35S-Label; ICN Biomedical, Costa Mesa, CA) for 5 h
in the presence of 10 mM BFA and then lysed on ice with
radioimmunoprecipitation lysis buffer RIPA (140 mM
NaCl, 8 mM NaHPO4, 2 mM NaH2PO4, 1% Nonidet-P40,
0.5% sodium deoxycholate, 0.05% SDS, 0.2% PMSF).
Pulse-chase experiments were processed as follows:
transfected cells were starved in the methionine-free
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DMEM containing 5% of dialyzed FBS in the presence of
10 mM BFA for 30 min before labeling. Then cells were
pulse-labeled for 20 min with 400 mCi/sample of
Trans35S-Label and chased in complete DMEM supple-
mented with 10 mM BFA. At the indicated time periods,
radiolabeled cells were lysed in RIPA.
CD4–Vpu binding experiments were all performed at
48 h posttransfection. Transfected cells were first
starved in methionine-free DMEM for 2 h in the presence
of 10 mM MG-132. Subsequently, 10 mM of BFA was
added for an additional 30 min. Then cells were pulse-
labeled for 20 min with 400 mCi/sample of Trans35S-
Label and chased in complete DMEM supplemented
with the same concentration of MG-132 and BFA. At the
indicated time periods, labeled cells were lysed in a
digitonin lysis buffer consisting of 0.5% digitonin, 10 mM
Tris–HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl, and 0.2%
PMSF, as described previously (Tiganos et al., 1997).
After lysis, the labeled cell lysates were obtained after
centrifugation in a HERMLE Z 231M Microcentrifuge
(4°C, 60 min at 14,000 rpm). Lysates were first immuno-
precipitated with anti-CD4 (OKT4) monoclonal antibodies
and subsequently immunoprecipitated with a rabbit anti-
Vpu serum as described previously (Tiganos et al., 1997).
Immunoprecipitates were analyzed on a 12.5% SDS–
polyacrylamide gel followed by autoradiography. Densi-
tometric analysis of autoradiograms was performed with
a Molecular Dynamics personal densitometer using an
Image Quant software version 3.22.
To assess Vpu-mediated enhancement of virion re-
lease, transfected HeLa–CD8 cells were metabolically
labeled with 150 mCi/sample of Trans35S-Label at 40 h
posttransfection for 8 h. The labeled cells were lysed in
RIPA buffer, and viral proteins were immunoprecipitated
with an HIV-1-positive human serum (Yao et al., 1992).
Immunofluorescence
Evaluation of cell-associated HIV-1 Vpu protein by im-
munofluorescence was performed as follows; COS-7
cells (3 3 105) were transfected with 12 mg of plasmid
DNA using the calcium phosphate method. At 48 h post-
transfection, cells were washed two times in PBS and
fixed for 30 min at room temperature in a solution of
ethanol–acetone (75%:25%). After fixation, cells were first
blocked in 2% nonfat milk in PBS for 20 min and then
incubated overnight with a rabbit anti-Vpu serum (Cohen
et al., 1988) diluted 1:2000 in PBS containing 2% nonfat
milk at 37°C. Cells were washed three times in PBS and
stained with FITC-conjugated goat anti-rabbit IgG
(GIBCO BRL, St. Lawrence, MA) diluted 1:100 in 2% non-
fat milk-PBS for 2 h at 37°C. Stained cells were washed
four times in PBS and observed at 1003 in oil emulsion
on a Zeiss fluorescence microscope.
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